ZEFIT is a contract research organization (CRO) specializing in early-stage drug discovery and preclinical contract research. They offer robust in vivo assay data to minimize development risks. Their zebrafish-based strategy enhances decision-making accuracy in preclinical trials, and their approach increases the likelihood of clinical trial success through better candidate screening and evaluation.

ZEFIT model focuses on in vivo zebrafish data for effective compound selection, utilizing integrated AI and automation for faster results. It is highly relevant to human diseases, especially in brain and metabolic issues, and allows for tailored testing and partnerships that encourage collaboration.

ZEFIT provides accurate and predictive in vivo data for early drug development, custom screening for CNS, oncology, metabolic, and toxicology studies, and generating data that aligns with IND-enabling studies and global preclinical standards.

The ZEFIT platform aids in drug discovery within a 3-year timeline, identifying promising compounds and optimizing them for further development. It uses advanced tools like biosignal tracking and blood-brain barrier testing to understand drug function. Combining this with AI-powered safety and effectiveness analysis in live models improves the success rate of new drug candidates.

Zebrafish embryos enable real-time observation of drug effects in the body, unlike lab-only tests. They are small, reproducible, and cost-effective for testing large compounds. Zebrafish share 82% of disease-related genes with humans, making them a strong model for predicting drug effects in humans. Early-stage embryos avoid animal testing restrictions, allowing faster and more ethical testing.

If you are looking for a preclinical testing, services you can find them at ZEFIT.

Click here if you are interested in ZEFIT services.

View more: Advanced Solutions for Predictive Preclinical Drug Development.